Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GRI Bio ( (GRI) ) has issued an update.
On December 10, 2025, GRI Bio announced positive topline results from its Phase 2a clinical trial of GRI-0621 for idiopathic pulmonary fibrosis (IPF). The study met its primary and secondary endpoints, showing that GRI-0621 was well tolerated and improved biomarkers related to fibrosis and lung repair. The results suggest GRI-0621’s potential as a disease-modifying treatment for IPF, offering a promising advance in the treatment landscape and potential value for patients and shareholders.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a biotechnology company focused on developing innovative immune cell modulators for treating inflammatory, fibrotic, and autoimmune diseases.
Average Trading Volume: 1,260,703
Technical Sentiment Signal: Sell
Current Market Cap: $4.41M
For a thorough assessment of GRI stock, go to TipRanks’ Stock Analysis page.